The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to see if it is safe and effective to give 1592U89 to HIV-positive adults. This study also examines the influence previous anti-HIV treatment has on the effectiveness of 1592U89.
Condition or disease
Drug: Abacavir sulfate
Patients receive open-label 1592U89 administered orally in combination with at least one other antiretroviral agent that the patient has not previously received.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
13 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Erythropoietin, G-CSF and GM-CSF.
Patients must have:
CD4+ cell count < 100 cells/mm3.
HIV-1 RNA > 30,000 copies/ml.
Signed, informed consent from parent or legal guardian for patient under 18 years of age.
Patients with the following conditions or symptoms are excluded:
Renal failure requiring dialysis.
Hepatic failure evident by grade 3/4 hyperbilirubinemia and AST 5 times the upper limit of normal.
Documented hypersensitivity to 1592U89.
Serious medical conditions, such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction, that would compromise the safety of the patient.
Participation in or ability to participate in an enrolling study of 1592U89.
At least 2 nucleoside reverse transcriptase inhibitors (NRTI) and one protease inhibitor (or intolerance to one protease inhibitor and one NRTI due to trying at least 2 different regimens with at least one protease inhibitor).
Alcohol or illicit drug use that may interfere with the patient's compliance.